GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Net Change in Cash

Mapi - Pharma (Mapi - Pharma) Net Change in Cash : $2.43 Mil (TTM As of Jun. 2015)


View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Mapi - Pharma's Net Change in Cash for the six months ended in Jun. 2015 was $3.13 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2015 was $2.43 Mil.

Mapi - Pharma Net Change in Cash Historical Data

The historical data trend for Mapi - Pharma's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Net Change in Cash Chart

Mapi - Pharma Annual Data
Trend Dec12 Dec13 Dec14
Net Change in Cash
1.53 -1.75 -0.77

Mapi - Pharma Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15
Net Change in Cash - - -0.07 -0.70 3.13

Mapi - Pharma Net Change in Cash Calculation

Mapi - Pharma's Net Change in Cash for the fiscal year that ended in Dec. 2014 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-6.186+5.417+0+0
=-0.77

Mapi - Pharma's Net Change in Cash for the quarter that ended in Jun. 2015

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0.265+-6.939+9.8+0
=3.13

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2015 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mapi - Pharma Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Net Change in Cash
Comparable Companies
NUVPF ADMD RSPI YBAO ULUR NRXCF ACUR LBLTF PUFXF BKIT RLMD IGC MYOS CBICF SBFM PVCT AQSZF PTLF AOLS APRI
Traded in Other Exchanges
N/A
Address
Website
http://www.mapi-pharma.com
Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.

Mapi - Pharma (Mapi - Pharma) Headlines